Paper No. 6
`
`Filed on behalf of Petitioner Metrics, Inc.
`Filed: July 29, 2014
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`METRICS, INC., MAYNE PHARMA, and
`JOHNSON MATTHEY, INC.
`Petitioners
`v.
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owners
`
`
`
`
`
`
`
`
`
`
`Case IPR2014-01043
`Patent 8,669,290
`
`
`
`Before PATRICK E. BAKER, Trial Paralegal
`
`CORRECTED Petition for Inter Partes Review of U.S. Patent No. 8,669,290
`Pursuant to the Patent Trial and Appeal Board’s July 22, 2014 Notice of
`Filing Date Accorded to Petition and Time for Filing Patent Owner
`Preliminary Response
`
`
`
`
`
`Mail Stop "PATENT BOARD"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`DM2\4995869.5
`
`
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`Partes Reeview of USSPN 8,6699,290
`
`
`
`
`
` Correctted Petitionn for Inter
`
`
`
`
`
`TABLE OOF CONTTENTS
`
`
`
`INNTRODUUCTION ....................................................
`
`
`
`
`
`EW ............II.  OOVERVIE
`
`................
`
`..................................
`
`
`
`I. 
`
`
`A. 
`B. 
`
`
`
`
`
`
`
`The ’’290 Patennt ................................................
`
`
`
`
`
`f the Prior The SScope and Content of
`
`
`
`Art ..........
`
`
`
`..................................
`
`A B
`
`
`
`PPage
`
`
`
`..................................
`
`
`
`..................................
`
`
`
`..................................
`
`..... 1 
`..... 1 
`..... 2 
`..... 4 
`..... 4 
`
`..... 5 
`
`..... 9 
`... 13 
`... 13 
`... 13 
`... 13 
`... 13 
`
`... 14 
`... 14 
`
`... 14 
`... 14 
`
`... 18 
`
`
`1. 
`2. 
`
`
`
`Aqueouss Opthalmmic Preparration of BBromfenacc ...............
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tyloxapol and Rellated Surffactants inn NSAID AAqueous
`
`
`
`Ophthallmic Prepaarations ....................
`
`..................................
`
`
`
`CC. 
`
`
`
`
`
`
`
`The DDifferences Betweenn the Challeenged Claiims and thee Prior
`
`
`
`
`Art ......................................................................
`
`..................................
`
`..... 6 
`
`..................................
`
`
`
`.................) ................§ 42.(a)(1))7 C.F.R. §TICES (37ORY NOTIV.  MMANDATO
`
`
`
`
`
`
`
`
`RAL OCEDUR04(a); PROF.R. § 42.10G (38 C.FIII.  SSTANDIN
`
`
`
`
`
`
`
`
`
`
`
`SSTATEMEENTS) ........................................................
`
`
`
`A. 
`
`
`
`
`
`1. 
`2. 
`7 C.F.R.
`Counsel (3Back-Up CLead and BC.  Desiggnation of
`
`
`
`
`
`
`
`
`
`§42.88(b)(3)): .....................................................
`
`
`
`Eachh Real Partyy-In-Intereest (37 C.F
`
`
`
`
`
`
`
`.R. § 42.8((b)(1)) .......................
`
`
`
`
`
`.................b)(2)) .........R. § 42.8(bs (37 C.F.Rted MattersB.  Noticce of Relat
`
`
`
`
`
`A B
`
`
`
`Judicial Matters: ..................................
`
`
`
`..................................
`
`
`
`.................Matters: .....Adminisstrative M
`
`
`
`
`
`
`..................................
`
`..................................
`
`C D
`
`
`
`
`
`
`
`.................2.8(b)(4)): .C.F.R. § 42ation (37 Cice InformaD.  Noticce of Servi
`
`
`
`
`
`
`STATEMEENT OF TTHE PRECCISE RELLIEF REQQUESTEDD AND
`
`
`
`
`THE REASSONS THHEREFORR (37 C.F.RR. § 42.22
`
`(a)) ............................
`
`
`
`
`
`
`.................TION ........NSTRUCTAIM CONAND CLAPATENT VI.  TTHE ’290 P
`
`L IN THEOF SKILLVII.  PPERSON O
`
`
`
` ART (“P
`OSA”) &
`
`STATE OOF THE
`
`
`AART ...........................
`
`
`..................................................
`
`..................................
`
`ST
`
`V. 
`
`
`
`i
`
`

`

`
`
`n for Inter ted Petition Correct
`
`
`
`
`
`
`
`9,290 SPN 8,669Partes Reeview of US
`
`
`
`
`
`
`
`DENTIFICATION OF CHALLLENGEE (37 C.F.RR. § 42.1044(b)) .........
`
`
`
`
`
`
`
`
`
`VIII.  ID
`
`
`AA. 
`
`
`
`
`
`Indeppendent Cllaims 1, 8 aand 14 .......................
`
`
`
`
`
`
`
`Ogawa iin View off Sallmannn ...............
`
`
`
`
`
`d 21—Quuaternary AAmmoniuum Salt ....
`
`
`
`..................................
`
`
`
`..................................
`
`
`
`..................................
`
`
`1. 
`
`
`
`
`
`..................................ims ..........endent ClaiBB.  Depe
`1. 
`
`Claims 22, 9, 15 an
`
`
`
`2. 
`3. 
`
`
`
`
`
`Claims 66, 12, 18 annd 24-pH
`
`
`
`Ranges ...
`
`
`
`..................................
`
`
`
`Claims 33 and 16——Sodium SSalt of Broomfenac ....................
`
`
`
`
`
`
`
`
`
`Claims 110, 20 andd 22 – Storrage Stabillity ............................
`
`
`
`
`
`... 20 
`... 21 
`... 21 
`... 33 
`... 33 
`... 36 
`
`
`
`Claims 44-5, 7, 11, 13, 17, 19,, 23 and 2
`
`
`5—Bromffenac Sodiium
`
`
`
`and Tylooxapol Concentratioons ...........
`... 38 
`
`..................................
`... 42 
`... 43 
`... 44 
`... 48 
`... 48 
`... 50 
`... 53 
`
`4. 
`5. 
`6. 
`
`
`
`
`
`ss .............obviousnescia of Nonoctive IndicCC.  Obje
`1. 
`
`
`
`
`No Unexxpected Reesults Oveer the Clossest Prior
`2. 
`
`
`SION .......IX.  CCONCLUS
`
`................
`Over
`
`ent Claim: DependeX.  AAppendix :
`
`
`
`
`s Would HHave Beenn Obvious
`
`
`thhe Prior AArt ............
`................
`
`..................................
`
`..................................
`
`
`
`
`
`
`
`Claims 226-30 – Prreservativee Efficacy
`
`
`
`
`
`
`
`Test .........................
`
`
`
`Other OObjective Indicia .......................
`
`
`
`
`
`
`
`..................................
`
`Art. .........
`
`
`
`..................................
`
`..................................
`
`
`
`..................................
`
`
`
`
`
`VICE CERTIIFICATE OF SERV
`
`
`
`..... 1 
`
`
`
`
`
`
`
`
`
`
`
`ii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`TABLE OF AUTHORITIES
`
`Cases
`
`Amneal Pharmaceuticals, LLC v. Supernus Pharmaceuticals, Inc.,
`IPR2013-00368, Paper 8 (December, 17, 2013) ................................................ 44
`
`Chapman v. Casner,
`315 F. App’x 294 (Fed. Cir. 2009) ............................................................... 36, 39
`
`Ex Parte Davis,
`80 USPQ 448 (Bd. App. 1948) ................................................................................ 12
`
`Friskit, Inc. v. Real Networks, Inc.,
`306 F. App’x 610 (Fed. Cir. 2009) ..................................................................... 47
`
`Galderma Labs., L.P. v. Tolmar, Inc.,
`737 F.3d 731 (Fed. Cir. 2013) ............................................................................ 36
`
`Genentech, Inc. v. Chiron Corp.,
`112 F.3d 495 (Fed. Cir. 1997) ............................................................................ 12
`
`In re Aller,
`220 F.2d 454, (C.C.P.A. 1955) ........................................................................... 37
`
`In re De Blauwe,
`736 F.2d 699 (Fed. Cir. 1984) ............................................................................ 45
`
`In re Merchant,
`575 F.2d 865 (C.C.P.A. 1978) ............................................................................ 45
`
`In re Peterson,
`315 F.3d 1325 (Fed. Cir. 2003) .................................................................... 37, 46
`
`Iron Grip Barbell Co., Inc. v. USA Sports, Inc.,
`392 F.3d 1317 (Fed. Cir. 2004) .......................................................................... 36
`
`KSR Int’l Co. v. Teleflex Inc.,
`550 U.S. 398 (2007) .................................................................................. 1, 15, 23
`
`Newell Cos., Inc. v. Kenney Mfg. Co.,
`864 F.2d 757 (Fed. Cir. 1988) ............................................................................ 44
`
`iii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`Ormco Corp. v. Align Tech., Inc.,
`463 F.3d 1299 (Fed. Cir. 2006) .......................................................................... 48
`
`Purdue Pharma Prods. L.P. v. Par Pharm., Inc.,
`377 F. App’x 978 (Fed. Cir. 2010) ..................................................................... 48
`
`Sinclair & Carroll Co., v. Interchemical Corp.,
`325 U.S. 327 (1945) ............................................................................................ 22
`
`Stratoflex, Inc. v. Aeroquip Corp.,
`713 F.2d 1530 (Fed. Cir. 1983) .................................................................... 47, 48
`
`Sundance, Inc. v. DeMonte Fabricating Ltd.,
`550 F.3d 1356 (Fed. Cir. 2008) .......................................................................... 27
`
`Tokai Corp. v. Eason Enters., Inc.,
`632 F.3d 1358 (Fed. Cir. 2011) .......................................................................... 49
`
`Wm. Wrigley Jr. Co. v. Cadbury Adams USA LLC,
`683 F.3d 1356 (Fed. Cir. 2012) .................................................................... 23, 27
`
`Statutes
`
`35 U.S.C. § 102(b) ............................................................................................passim
`
`35 U.S.C. § 112 .................................................................................................passim
`
`Regulations
`
`37 C.F.R. § 42.106(a) ................................................................................................. 9
`
`
`
`
`
`
`
`iv
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Corrected Petitioner’s Exhibit List
`
`Metrics
`Exhibit #
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`Description
`
`Sawa et al., U.S. Patent No. 8,669,290, "Aqueous Liquid Preparation
`Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid". This
`exhibit was replaced with revised Exhibit 1053, adding sequential
`numbering to each page of the exhibit.
`Hara, Yoshiyuki , "Bromfenac sodium hydrate," Clinics & Drug
`Therapy 19:1014-1015 (2002)
`Declaration of Professor Uday B. Kompella, Ph.D., replaced with
`revised Exhibit 1086, noting citations to the revised Exhibits.
`Ogawa et al., U.S. Patent No. 4,910,225 "Locally Administrable
`Therapeutic Composition for Inflammatory Disease". This exhibit
`was replaced with revised Exhibit 1054, adding sequential numbering
`to each page of the exhibit.
`Desai et al., U.S. Patent No. 5,603,929, "Preserved Ophthalmic Drug
`Compositions Containing Polymeric Quaternary Ammonium
`Compounds" This exhibit was replaced with revised Exhibit 1055,
`adding sequential numbering to each page of the exhibit.
`Desai, et al., U.S. Patent No. 5,558,876, "Topical Ophthalmic Acidic
`Drug Formulations". This exhibit was replaced with revised Exhibit
`1056, adding sequential numbering to each page of the exhibit.
`Certified English translation of "Bromfenac sodium hydrate" in the
`Japanese Pharmacopoeia 2001 Edition: 27-29, Yakuji Nippo Limited
`(2001). This exhibit was replaced with revised Exhibit 1057, adding
`sequential numbering to each page of the exhibit.
`FDA approved "BROMDAY™ (bromfenac ophthalmic solution,
`.09%) Product Label," U.S. Approval: March 24, 2005, ISTA
`Pharmaceuticals, Inc.
`Sallmann et al., U.S. Patent No. 6,107,343, "Ophthalmic And Aural
`Compositions Containing Diclofenac Potassium"
`
`v
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`Description
`
`Guttman et al., "Solubilization of Anti-inflammatory steroids by
`Aqueous Solutions of Triton-WR-1339," Journal of Pharmaceutical
`Sciences 50: 305-307 (1961). This exhibit was replaced with revised
`Exhibit 1058, adding sequential numbering to each page of the
`exhibit.
`Fu et al., Australian Patent No. AU-B-22042/88, "Preservative
`System For Ophthalmic Formulations". This exhibit was replaced
`with revised Exhibit 1059, adding sequential numbering to each page
`of the exhibit.
`Yasueda et al., U.S. Patent No. 6,274,609, "Aqueous Liquid
`Pharmaceutical Composition Containing as Main Component
`Benzopyran Derivative". This exhibit was replaced with revised
`Exhibit 1060, adding sequential numbering to each page of the
`exhibit.
`"Orange Book: Approved Drug Products with Therapeutic
`Equivalence Evaluations," Appl. No. N203168, U.S. FDA, accessed
`at
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?
`Appl_No=203168&Product_No=001&table1=OB_Rx
`"Orange Book: Approved Drug Products with Therapeutic
`Equivalence Evaluations," Appl. No. N203168, Active Ingredient
`Bromfenac Sodium, accessed at
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?App
`l_No=203168&TABLE1=OB_Rx, last accessed on January 24, 2014
`U.S. Patent Application No. 13/687,242, 2/11/14, Notice of
`Allowance. This exhibit was replaced with revised Exhibit 1061,
`adding sequential numbering to each page of the exhibit.
`“ophthalmic,” Webster’s Deluxe Unabridged Dictionary: 1254, New
`Twentieth Century Dictionary/Simon and Shuster (1979). This exhibit
`was replaced with revised Exhibit 1062, adding sequential numbering
`to each page of the exhibit.
`Kapin, et al., International Patent No. WO 2002/13804, “Method for
`Treating Angiogenesis-Related Disorders Using Benzoyl Phenylacetic
`Acid”
`
`vi
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`Description
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`Flach, Allan., “Topical Nonsteroidal Antiinflammatory Drugs for
`Ophthalmic Uses,” Ophthalmic NSAIDs: 77-83 (1996)
`Schott, H., "Comparing the Surface Chemical Properties and the
`Effect of Salts on the Cloud Point of a Conventional Nonionic
`Surfactant, Octoxynol 9 (Triton X-100), and of Its Oligomer,
`Tyloxapol (Triton WR-1339)," Journal of Colloid and Interface
`Science 205: 496-502 (1998)
`Regev, O., et al., "Aggregation Behavior of Tyloxapol, a Nonionic
`Surfactant Oligomer, in Aqueous Solution," Journal of Colloid and
`Interface Science 210: 8-17 (1999)
`Aviv, H., International Patent No. WO 94/05298, "Submicron
`Emulsions as Ocular Drug Delivery Vehicles". This exhibit was
`replaced with revised Exhibit 1063, adding sequential numbering to
`each page of the exhibit.
`Bergamini et al., U.S. Patent No. 5,597,560, "Diclofenac And
`Tobramycin Formulations For Ophthalmic And Otis Topical Use".
`This exhibit was replaced with revised Exhibit 1064, adding
`sequential numbering to each page of the exhibit.
`U.S. Patent Application No. 13/687,242, Applicant Remarks in
`support of amendment, November 28, 2012. This exhibit was replaced
`with revised Exhibit 1065, adding sequential numbering to each page
`of the exhibit.
`November 16, 1994 Desai Declaration under 37 CFR §1.132(Desai I)
`and July 2, 1996 Desai Declaration under 37 CFR §1.132 (Desai II).
`This exhibit was replaced with revised Exhibit 1066, adding
`sequential numbering to each page of the exhibit.
`
`vii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`Description
`
`1025
`
`1026*1
`
`1027*
`
`1028*
`
`U.S. Patent Application No. 13/687,242, Applicant
`Arguments/Remarks Made in an Amendment, 10/22/2013, pp. 9-15
`"monohydrate," Webster’s New World Dictionary of the American
`Language: 920, New World Dictionaries / Simon and Schuster
`(1980). This exhibit was replaced with revised Exhibit 1067, adding
`sequential numbering to each page of the exhibit.
`"Voltaren," Orange Book: Approved Drug Products with Therapeutic
`Equivalence Evaluations, Appl. No. N020037, U.S. FDA, accessed at
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?App
`l_No=020037&TABLE1=OB_Rx
`Yanni et al., U.S. Patent No. 5,475,034, "Topically Administrable
`Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for
`Treatment of Ophthalmic Inflammatory Disorders". This exhibit was
`replaced with revised Exhibit 1068, adding sequential numbering to
`each page of the exhibit.
`"ISTA Pharmaceuticals Submits New Drug Application for Xibrom™
`QD (once-daily), News Release, ISTA Pharmaceuticals (December
`20, 2007)
`Prince, S., et al., "Analysis of benzalkonium chloride and its
`homologs: HPLC versus HPCE," Journal of Pharmaceutical and
`Biomedical Analysis 19: 877-882, Elsevier Science B.V., Netherlands
`(1999)
`"Acular®" and "Azopt™," Physician’s Desk Reference 54: 486-487,
`491-492 (2000). This exhibit was replaced with revised Exhibit 1069,
`adding sequential numbering to each page of the exhibit.
`Doughty, M., "Medicines Update for optical practitioners- Part 11.,"
`Optician 5853 (223), (2002). This exhibit was replaced with revised
`Exhibit 1070, adding sequential numbering to each page of the
`exhibit.
`
`1 All exhibits listed with an asterisk are exhibits cited only in the Declaration
`
`1029*
`
`1030*
`
`1031*
`
`1032*
`
`of Professor Uday B. Kompella, Ph.D. (EX1003, replaced with EX1086).
`
`viii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`1033*
`
`1034*
`
`1035*
`
`1036*
`
`1037*
`
`1038*
`
`1039*
`
`Description
`
`Reddy, Indra K., Ocular Therapeutics and Drug Delivery: A Multi-
`Disciplinary Approach: 42-43, 390 (1996). This exhibit was replaced
`with revised Exhibit 1071, adding sequential numbering to each page
`of the exhibit.
`Fan, T., "Determination of Benzalkonium Chloride in Ophthalmic
`Solutions Containing Tyloxapol by Solid-Phase Extraction and
`Reversed-Phase High-Performance Liquid Chromatography," Journal
`of Pharmaceutical Sciences 82
`(11): 1172-1174, American
`Pharmaceutical Association, United States (1993). This exhibit was
`replaced with revised Exhibit 1072, adding sequential numbering to
`each page of the exhibit.
`Wong, Michelle, International Patent No. WO 94/15597, "Ophthalmic
`Compositions Comprising Benzyllauryldimethylammonium Chloride"
`(filed January 11, 1993; issued July 21, 1994). This exhibit was
`replaced with revised Exhibit 1073, adding sequential numbering to
`each page of the exhibit.
`Guy et al., U.S. Patent No. 5,540,930, "Suspension of Loteprednol
`Etabonate for Ear, Eye, or Nose Treatment" (filed October 25, 1993;
`issued July 30, 1996). This exhibit was replaced with revised Exhibit
`1074, adding sequential numbering to each page of the exhibit.
`FDA approved "ALREX™ (loteprednol etabonate ophthalmic
`suspension) 0.2% Product Label," U.S. Approval: 1998, Bausch &
`Lomb Pharmaceuticals. This exhibit was replaced with revised
`Exhibit 1075, adding sequential numbering to each page of the
`exhibit.
`FDA approved "LOTEMAX™ (loteprednol etabonate ophthalmic
`suspension) 0.5% Product Label," U.S. Approval: 1998, Bausch &
`Lomb Pharmaceuticals. This exhibit was replaced with revised
`Exhibit 1076, adding sequential numbering to each page of the
`exhibit.
`"TOBRADEX®" Physician’s Desk Reference 54: 490 (2000). This
`exhibit was replaced with revised Exhibit 1077, adding sequential
`numbering to each page of the exhibit.
`
`ix
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`1040*
`
`1041*
`
`1042*
`
`1043*
`
`1044*
`
`1045*
`
`1046*
`
`1047*
`
`1048*
`
`Description
`
`"Alomide® 0.1%" Physician’s Desk Reference 50: 469 (1996). This
`exhibit was replaced with revised Exhibit 1078, adding sequential
`numbering to each page of the exhibit.
`Johnson, R., et al., U.S. Patent No. 2,880,130, "Anti-Inflammatory
`Steroid Solutions". This exhibit was replaced with revised Exhibit
`1079, adding sequential numbering to each page of the exhibit.
`Johnson, R., et al., U.S. Patent No. 2,880,138, "Anti-Inflammatory
`Steroid Solutions". This exhibit was replaced with revised Exhibit
`1080, adding sequential numbering to each page of the exhibit.
`Kawabata et al., Canadian Patent No. CA 2 383 971 A1,
`“Prophylactic and Therapeutic Medicaments for Ophthalmic Uses”.
`This exhibit was replaced with revised Exhibit 1081, adding
`sequential numbering to each page of the exhibit.
`Patani, G., et al., "Bioisoterism: A Rational Approach in Drug
`Design," Chem. Rev. 96: 3147-3176 (1996).
`FDA approved "XIBROM™ (bromfenac ophthalmic solution, .09%)
`Product Label," ISTA Pharmaceuticals, Inc.
`Senju Pharmaceutical Co., Ltd. Press Releases, "The approval of
`BRONUCK® (bromfenac sodium hydrate ophthalmic solution) as an
`import drug
`in China," http://www.senju.co.jp/, accessed at
`http://www.senju.co.jp/english/news/__icsFiles/afieldfile/2009/11/18/
`2009111814br.pdf, published November 17, 2009, 1 page. This
`exhibit was replaced with revised Exhibit 1082, adding sequential
`numbering to each page of the exhibit.
`FDA approved "PROLENSA™ (bromfenac ophthalmic solution,
`0.07%) Product Label," U.S. Approval: April 5, 2013, Bausch &
`Lomb Incorporated
`"Borax (Sodium tetraborate)," Biochemicals and Reagents: 175,
`Sigma-Aldrich (2000-2001). This exhibit was replaced with revised
`Exhibit 1083, adding sequential numbering to each page of the
`exhibit.
`
`x
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`1049*
`
`1050*
`
`1051*
`
`1052*
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`Description
`
`Ali, et al., U.S. Patent No. 6,071,904, "Process for Manufacturing
`Ophthalmic Suspensions". This exhibit was replaced with revised
`Exhibit 1084, adding sequential numbering to each page of the
`exhibit.
`Story, M., et al., European Patent No. 0274870, "Micelles containing
`a non-steroidal antiinflammatory compound" (filed December 12,
`1987; issued July 7, 1988)
`“Duract™,” Physician’s Desk Reference 52:3035-3037 (1998). This
`exhibit was replaced with revised Exhibit 1085, adding sequential
`numbering to each page of the exhibit.
`Curriculum Vitae of Professor Uday B. Kompella, Ph.D.
`Sawa et al., U.S. Patent No. 8,669,290, "Aqueous Liquid Preparation
`Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid"
`Ogawa et al., U.S. Patent No. 4,910,225 "Locally Administrable
`Therapeutic Composition for Inflammatory Disease"
`Desai et al., U.S. Patent No. 5,603,929, "Preserved Ophthalmic Drug
`Compositions Containing Polymeric Quaternary Ammonium
`Compounds"
`Desai, et al., U.S. Patent No. 5,558,876, "Topical Ophthalmic Acidic
`Drug Formulations"
`Certified English translation of "Bromfenac sodium hydrate" in the
`Japanese Pharmacopoeia 2001 Edition: 27-29, Yakuji Nippo Limited
`(2001)
`Guttman et al., "Solubilization of Anti-inflammatory steroids by
`Aqueous Solutions of Triton-WR-1339," Journal of Pharmaceutical
`Sciences 50: 305-307 (1961)
`Fu et al., Australian Patent No. AU-B-22042/88, "Preservative
`System For Ophthalmic Formulations"
`Yasueda et al., U.S. Patent No. 6,274,609, "Aqueous Liquid
`Pharmaceutical Composition Containing as Main Component
`Benzopyran Derivative"
`
`xi
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`Description
`
`1061
`
`1062
`
`1063
`
`1064
`
`1065
`
`1066
`
`1067
`
`1068
`
`1069*
`
`1070*
`
`1071*
`
`1072*
`
`1073*
`
`U.S. Patent Application No. 13/687,242, 2/11/14, Notice of
`Allowance
`“ophthalmic,” Webster’s Deluxe Unabridged Dictionary: 1254, New
`Twentieth Century Dictionary/Simon and Shuster (1979)
`Aviv, H., International Patent No. WO 94/05298, "Submicron
`Emulsions as Ocular Drug Delivery Vehicles"
`Bergamini et al., U.S. Patent No. 5,597,560, "Diclofenac And
`Tobramycin Formulations For Ophthalmic And Otis Topical Use"
`U.S. Patent Application No. 13/687,242, Applicant Remarks in
`support of amendment, November 28, 2012
`November 16, 1994 Desai Declaration under 37 CFR §1.132(Desai I)
`and July 2, 1996 Desai Declaration under 37 CFR §1.132 (Desai II).
`"monohydrate," Webster’s New World Dictionary of the American
`Language: 920, New World Dictionaries / Simon and Schuster (1980)
`Yanni et al., U.S. Patent No. 5,475,034, "Topically Administrable
`Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for
`Treatment of Ophthalmic Inflammatory Disorders"
`"Acular®" and "Azopt™," Physician’s Desk Reference 54: 486-487,
`491-492 (2000)
`Doughty, M., "Medicines Update for optical practitioners- Part 11.,"
`Optician 5853 (223), (2002)
`Reddy, Indra K., Ocular Therapeutics and Drug Delivery: A Multi-
`Disciplinary Approach: 42-43, 390 (1996)
`Fan, T., "Determination of Benzalkonium Chloride in Ophthalmic
`Solutions Containing Tyloxapol by Solid-Phase Extraction and
`Reversed-Phase High-Performance Liquid Chromatography," Journal
`of Pharmaceutical Sciences 82
`(11): 1172-1174, American
`Pharmaceutical Association, United States (1993)
`Wong, Michelle, International Patent No. WO 94/15597, "Ophthalmic
`Compositions Comprising Benzyllauryldimethylammonium Chloride"
`(filed January 11, 1993; issued July 21, 1994)
`
`xii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`Metrics
`Exhibit #
`
`1074*
`
`1075*
`
`1076*
`
`1077*
`1078*
`1079*
`
`1080*
`
`1081*
`
`1082*
`
`1083*
`
`1084*
`
`1085*
`1086
`
`Description
`
`Guy et al., U.S. Patent No. 5,540,930, "Suspension of Loteprednol
`Etabonate for Ear, Eye, or Nose Treatment" (filed October 25, 1993;
`issued July 30, 1996)
`FDA approved "ALREX™ (loteprednol etabonate ophthalmic
`suspension) 0.2% Product Label," U.S. Approval: 1998, Bausch &
`Lomb Pharmaceuticals
`FDA approved "LOTEMAX™ (loteprednol etabonate ophthalmic
`suspension) 0.5% Product Label," U.S. Approval: 1998, Bausch &
`Lomb Pharmaceuticals
`"TOBRADEX®" Physician’s Desk Reference 54: 490 (2000)
`"Alomide® 0.1%" Physician’s Desk Reference 50: 469 (1996)
`Johnson, R., et al., U.S. Patent No. 2,880,130, "Anti-Inflammatory
`Steroid Solutions".
`Johnson, R., et al., U.S. Patent No. 2,880,138, "Anti-Inflammatory
`Steroid Solutions"
`Kawabata et al., Canadian Patent No. CA 2 383 971 A1,
`“Prophylactic and Therapeutic Medicaments for Ophthalmic Uses”
`Senju Pharmaceutical Co., Ltd. Press Releases, "The approval of
`BRONUCK® (bromfenac sodium hydrate ophthalmic solution) as an
`import drug
`in China," http://www.senju.co.jp/, accessed at
`http://www.senju.co.jp/english/news/__icsFiles/afieldfile/2009/11/18/
`2009111814br.pdf, published November 17, 2009, 1 page.
`"Borax (Sodium tetraborate)," Biochemicals and Reagents: 175,
`Sigma-Aldrich (2000-2001)
`Ali, et al., U.S. Patent No. 6,071,904, "Process for Manufacturing
`Ophthalmic Suspensions"
`“Duract™,” Physician’s Desk Reference 52:3035-3037 (1998).
`Declaration of Professor Uday B. Kompella, Ph.D.
`
`xiii
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`I.
`
`INTRODUCTION
`Metrics, Inc. (“Petitioner”) petitions for Inter Partes Review, seeking
`
`cancellation of claims 1-30 (“challenged claims”) of U.S. Patent No. 8,669,290
`
`(“the ’290 patent”) (EX1001, replaced with EX1053), owned by Senju
`
`Pharmaceutical Co., Ltd. (“Senju”).
`
`II. OVERVIEW
`Claims 1-30 of the ’290 patent are unpatentable for failing to satisfy the
`
`nonobviousness requirement of 35 U.S.C. § 103. The alleged “inventions” involve
`
`only (1) the “simple and obvious substitution of one known element for another to
`
`obtain predictable results” over what was already taught and used in the prior art;
`
`(2) “choosing from a finite number of identified, predictable solutions,” with a
`
`reasonable expectation of success; and/or (3) the mere obvious modification of
`
`prior art teachings, with a reasonable expectation of success. As such, each of
`
`these claims is invalid as a matter of law. KSR Int’l Co. v. Teleflex, Inc., 550 U.S.
`
`398, 417 (2007).
`
`In essence the challenged claims all are directed to a stable aqueous
`
`formulation of bromfenac (a non-steroidal anti-inflammatory drug (NSAID)) with
`
`tyloxapol (a non-ionic surfactant). Tyloxapol was a known non-ionic surfactant in
`
`aqueous formulations of NSAIDs and bromfenac was a known NSAID previously
`
`formulated with another non-ionic surfactant, polysorbate 80. Thus, the inventors
`
`
`
`1
`
`

`

`
`
` Correctted Petitionn for Inter
`
`
`
`
`
`
`
`
`
`
`
`hallenged of the aaqueous preparations of the c
`
`
`
`
`
`
`Partes Reeview of USSPN 8,6699,290
`
`
`
`
`
`
`
`claims off the ’290
`
`
`
`patent simmply
`
`
`
`
`
`
`
`
`
`
`
`switched polysorbbate 80 for tyloxopol (both welll-known noon-ionic suurfactants)
`
`
`
`
`
`. Or
`
`viewed
`
`
`
`another wway, the innventors oof the challlenged cl
`
`
`
`
`
`
`
`
`
`aims of thhe ’290 paatent
`
`
`
`merely
`
`switched
`
`
`
`diclofenacc for brommfenac (botth well-knnown struccturally simmilar
`
`
`
`
`
`
`
`
`
`
`
`NSAID
`
`
`
`
`s). Swappping knowwn alternaatives fromm the priorr art, accoording to
`
`
`
`
`
`
`
`
`
`their
`
`
`
`known ffunctions tto achieve predictable results, i
`
`
`
`
`
`
`
`
`
`s not innovvation.
`
`
`
`’290 pateent are dirrected to sstable aquueous
`
`
`
`
`
`
`
`
`
`
`
`A T
`
`A.
`
`The challennged claimms of the
`
`
`
` The ’290 Patennt
`
`
`
`liquid ppreparationns for ophthhalmic admministratio
`
`
`
`
`
`
`
`n. Indepe
`
`
`
`ndent claimms 1, 8 annd 14
`
`
`
`
`
`are reprroduced beelow:
`
`
`
` a
`
`
`
`
`
`1. AA stable aquueous liquuid preparaation compprising: (a)
`in
`first
`
`
`
`
`componennt; and (b)) a secondd componeent; where
`first
`
`compoonent
`is
`
`
`2-aamino-3-(4(4-
`the
`
`
`
`
`
`brommobenzoyl)pphenylaceetic acid orr a pharmaacological
`ly
`
`wherein thhe
`
`accepptable salt
`
`
`thereof orr a hydratee thereof,
`1
`
`
`
`
`
`hydraate is at lleast one sselected frfrom a 1/22 hydrate,
`
`
`
`
`
`
`hydraate, and 3//2 hydrate;; the first ccomponennt is the soole
`
`
`pharmmaceuticall active
`
`
`ingredientt containned
`in
`
`thhe
`e second
`
`prepaaration; th
`
`
`componennt is tyloxxapol and
`is
`nt
`
`
`liquid prepparation inn an amoun
`nt sufficie
`
`preseent in said
`
`
`
`
`
`
`to staabilize saidd first commponent; annd whereinn said stabble
`
`
`liquidd preparaation
`is
`
`formulatted
`for
`
`ophthalmmic
`
`administration.
`
`2
`
`

`

` Corrected Petition for Inter Partes Review of USPN 8,669,290
`
`
`8. A stable aqueous liquid preparation comprising:
`(a) a first component; and (b) a second component;
`the
`first
`component
`is 2-amino-3-(4-
`wherein
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof, wherein the
`hydrate is at least one selected from a 1/2 hydrate, 1
`hydrate, and 3/2 hydrate the first component is the sole
`pharmaceutical active
`ingredient contained
`in
`the
`preparation; the second component is tyloxapol; wherein
`said stable
`liquid preparation
`is
`formulated
`for
`ophthalmic administration; and wherein
`the stable
`aqueous liquid preparation is characterized in that greater
`than about 90% of the original amount of the first
`component remains in the preparation after storage at
`about 60° C. for 4 weeks.
`
` A stable aqueous liquid preparation comprising:
`14.
`(a) a first component; and (b) a second component;
`the
`first
`component
`is 2-amino-3-(4-
`wherein
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof, wherein the
`hydrate is at least one selected from a 1/2 hydrate, 1
`hydrate, and 3/2 hydrate; the first component is the sole
`pharmaceutical active
`ingredient contained
`in
`the
`preparation; the second component is tyloxapol; wherein
`said stable
`liquid preparation
`is
`formulated
`for
`
`3
`
`

`

`
`
` Correctted Petitionn for Inter
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Partes Reeview of USSPN 8,6699,290
`
`
`
`
`
`ophthhalmic addministratioon; proviided that
`
`
`
`
`prepaaration doees not incluude mannittol.
`
`the liqu
`
`id
`
`
`
`(EX10001, replacedd with EX1053, 12:11-13; 12:411-53; 13:144-25)2 (emmphasis addded).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Inn pertinentt part, eachh of the thhree indepeendent claiims of the
`
`
`
`
`
`
`
`
`
`
`
`
`
`directedd to a stabble, aqueouus liquid ppreparationn comprisiing two coomponents
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`bromfennac (or its salts and hhydrates); aand (2) tylooxapol.
`
`
`
`
`
`
`
`
`
`
`
`’290 pateent is
`
`: (1)
`
`at a
`
`
`
`Inn the conttext of thee ’290 pateent, the woord “compprising’ mmeans that,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`minimuum, the claaimed ophhthalmic foormulation
`
`
`
`
`
`
`
`
`
`the solee active ingredient) aand tyloxoopol. Howwever, the
`
`
`
`
`
`
`
`
`
`must conntain both
`
`
`
`bromfenacc (as
`
`
`
`formulatioon may furrther
`
`
`
`
`
`include
`
`
`
`any otherr unlisted
`
`
`
`ingredientt, includinng “convenntional varrious addittives
`
`
`
`
`
`
`
`
`
`such as
`
`
`
`isotonics,, buffers, tthickeners, stabilizerss, chelatinng agents, ppH contro
`
`
`
`
`
`
`
`
`
`
`
`lling
`
`agents,
`
`
`
`perfumes aand the likke.” (EX10001, replacced with EXX1053, 6:99-12; claimms 7,
`
`
`
`
`
`
`
`
`
`
`
`
`
`13, 19,
`25)
`
`
`
`BB.
`
`
`
`
`
`of the Prid Content The SScope and
`
`
`
`or Art
`
`
`
`Aqueouss Opthalmmic Preparration of BBromfenacc
`
`
`
`
`
`
`
`
`
`
`1.
`
`
`
`
`
`BBromfenac,, diclofenaac and ketoorolac weree well-knowwn NSAIDDs useful fofor
`
`
`
`
`
`
`
`
`
`
`
`
`
`treatingg inflammaation in the eye. (EX11002, 10144:1:2; EX1
`
`
`
`
`
`
`
`
`
`
`
`0033, replaaced with
`
`
`
`
`
`
`
`
`
`
`
`
`2 Citations aare as folloows: X:YYY-ZZ (col:llines; patennt); X:Y:Z
`
`
`
`
`
`(page:cool:para; jouurnal articlle); X:Y (ppage:para; jjournal artticle).
`
`
`
`
`
`
`
`
`
`
`
`4
`
`

`

` Corrected Petit